Overview

Ivermectin is a semi-synthetic derivative of avermectin B1, a macrocyclic lactone compound produced by the soil bacterium Streptomyces avermitilis. Discovered by Satoshi Ōmura and William Campbell (who shared the 2015 Nobel Prize in Physiology or Medicine for this work), ivermectin has transformed global health as one of the most important antiparasitic drugs ever developed. It acts by binding to glutamate-gated chloride channels in invertebrate nerve and muscle cells, causing hyperpolarization, paralysis, and death of parasites. In humans, it is FDA-approved for onchocerciasis (river blindness), strongyloidiasis, and topically for rosacea and head lice. The Mectizan Donation Program has distributed over 4 billion doses globally, making it one of the most widely administered drugs in history.

Beyond its established antiparasitic role, ivermectin demonstrates a broad spectrum of pharmacological activities under investigation. It has shown anti-inflammatory properties through inhibition of NF-κB signaling and reduction of cytokine production, anti-cancer effects via PAK1 inhibition and modulation of the Wnt/β-catenin and Akt/mTOR pathways, and antiviral activity against numerous RNA viruses in vitro, including dengue, Zika, HIV, and influenza. Ivermectin also modulates the immune system through effects on farnesoid X receptor (FXR) and other nuclear receptors. Its antiviral mechanisms appear to involve inhibition of importin α/β1-mediated nuclear import, which many viruses exploit to suppress host antiviral responses.

While ivermectin's safety profile at standard antiparasitic doses (150–200 mcg/kg) is well established over decades of mass drug administration, its repurposing for conditions beyond parasitology remains an active area of research requiring rigorous clinical trial evidence. The drug is metabolized primarily by CYP3A4, and interactions with inhibitors of this enzyme should be monitored. Ivermectin has also demonstrated synergy with other antiparasitic and immunomodulatory approaches. Its anti-inflammatory profile positions it alongside compounds like artemisinin and berberine that have transitioned from traditional anti-infective roles to broader investigation in metabolic and inflammatory conditions. The drug's remarkable safety record and low cost continue to motivate research into new therapeutic applications.

Mechanism of Action

Ivermectin is a macrocyclic lactone derived from avermectins produced by Streptomyces avermitilis. Its primary antiparasitic mechanism involves selective, high-affinity binding to glutamate-gated chloride ion channels (GluCls), which are found exclusively in invertebrate nerve and muscle cells. Upon binding, ivermectin locks these channels in a permanently open conformation, causing sustained influx of chloride ions that hyperpolarizes the cell membrane. In neurons, this prevents action potential propagation; in muscle cells, it produces flaccid paralysis. The affected parasites are unable to feed, move, or reproduce, leading to their death and expulsion.

Ivermectin also potentiates the activity of gamma-aminobutyric acid (GABA) at GABA-gated chloride channels in invertebrates, further enhancing inhibitory neurotransmission and compounding the paralytic effect. Its selective toxicity for invertebrates arises from two factors: vertebrates do not possess glutamate-gated chloride channels, and mammalian GABA receptors in the central nervous system are protected by the blood-brain barrier, which ivermectin does not readily cross at therapeutic doses. This provides a wide safety margin for vertebrate hosts.

Beyond its established antiparasitic applications, ivermectin has demonstrated anti-inflammatory and immunomodulatory properties in preclinical studies. It can inhibit NF-kB pathway activation and reduce pro-inflammatory cytokine production. There has also been interest in potential antiviral mechanisms, including inhibition of importin alpha/beta1-mediated nuclear transport, though the clinical relevance of these in vitro findings at achievable human plasma concentrations remains a subject of ongoing investigation.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Ivermectin

Common Side Effects

• Mazzotti reaction (when treating Onchocerca volvulus): fever, pruritus, rash, lymphadenopathy, arthralgia, and hypotension due to die-off of microfilariae — NOT an allergic reaction to ivermectin itself
• Dizziness, headache, and somnolence
• Nausea, diarrhea, and abdominal pain
• Mild transient transaminase elevation
• Fatigue and asthenia

Serious Adverse Effects

• Neurotoxicity (CRITICAL): ivermectin is a GABA-A and glutamate-gated chloride channel agonist; in patients with compromised blood-brain barrier or P-glycoprotein dysfunction, CNS penetration increases dramatically — causing ataxia, tremor, confusion, seizures, coma, and death
• Severe Mazzotti reaction: in heavy Onchocerca or Loa loa infections, massive microfilarial die-off can cause encephalopathy, respiratory distress, and cardiovascular collapse
• Loa loa encephalopathy: in patients with high Loa loa microfilarial counts (>30,000/mL), ivermectin can cause fatal encephalopathy; screen before treatment in endemic areas
• Hepatotoxicity: rare idiosyncratic liver injury; elevated ALT/AST reported
• Stevens-Johnson syndrome / toxic epidermal necrolysis: extremely rare but documented

Contraindications

• Known hypersensitivity to ivermectin or any formulation excipient
• Co-infection with Loa loa with high microfilarial burden (>30,000 microfilariae/mL) — risk of fatal encephalopathy
• Concurrent use of drugs that inhibit P-glycoprotein or CYP3A4 at the blood-brain barrier
• Children weighing <15 kg (safety not established)
• Severe hepatic impairment

Drug Interactions

• P-glycoprotein inhibitors (verapamil, cyclosporine, quinidine, ketoconazole): CRITICAL — reduced P-gp efflux at the BBB allows ivermectin CNS accumulation, causing neurotoxicity
• CYP3A4 inhibitors (ritonavir, clarithromycin, itraconazole): increased ivermectin plasma levels and half-life
• Benzodiazepines and other GABAergic drugs: additive CNS depression through shared GABA receptor modulation
• Warfarin: ivermectin may enhance anticoagulant effect; INR monitoring required
• Alcohol: additive CNS depressant effects

Population-Specific Considerations

• Pregnancy: Category C; crosses placental barrier; associated with cleft palate in animal studies at high doses; avoid in first trimester; use in second/third trimester only if clearly needed
• Lactation: excreted in breast milk in low concentrations; WHO considers compatible with breastfeeding at single antiparasitic doses, but caution with repeated dosing
• Children <15 kg: safety and efficacy not established; CNS vulnerability due to immature BBB
• Elderly: increased susceptibility to CNS effects; start with weight-based standard dosing and monitor closely
• Patients with CNS disorders (epilepsy, meningitis, African trypanosomiasis): compromised BBB increases neurotoxicity risk; avoid or use with extreme caution

Pharmacokinetic Profile